Aradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis

HAYWARD, Calif.--(BUSINESS WIRE) July 27, 2017 -- Aradigm Corporation (NASDAQ: ARDM) (the " Company " ) today announced it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq ™ for the treatment of...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news